Benralizumab in severe eosinophilic asthma in real life: confirmed effectiveness and contrasted effect on sputum eosinophilia versus exhaled nitric oxide fraction – PROMISE

BACKGROUND: Randomised controlled trials have shown that benralizumab, an anti-interleukin-5 receptor monoclonal antibody, reduces exacerbations and oral corticosteroid dose and improves asthma control and lung function in severe eosinophilic asthma. The aim of this study was to confirm results of r...

Descripción completa

Detalles Bibliográficos
Autores principales: Schleich, Florence, Moermans, Catherine, Seidel, Laurence, Kempeneers, Céline, Louis, Gilles, Rogister, Florence, Tombu, Sophie, Pottier, Laurence, Poirrier, Anne-Lise, Ziant, Stéphanie, Henket, Monique, Sanchez, Carole, Paulus, Virginie, Guissard, Françoise, Donneau, Anne-Françoise, Louis, Renaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680030/
https://www.ncbi.nlm.nih.gov/pubmed/38020567
http://dx.doi.org/10.1183/23120541.00383-2023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10680030/
https://www.ncbi.nlm.nih.gov/pubmed/38020567
http://dx.doi.org/10.1183/23120541.00383-2023

Ejemplares similares